Fecal elimination of metabolites also occurs, particularly following oral administration, though quantitative contribution of each elimination pathway varies by route and dose
The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint
In preclinical models, BPC-157 is investigated for its activity across several interconnected signaling cascades, including the VEGFR2/eNOS angiogenic axis, the FAK-paxillin pathway in tendon fibroblasts, and ERK1/2-mediated transcription factor activation
Dosage protocols for injectable GHK-Cu, BPC-157, and TB-500 blends typically include 200-300 mcg/day for GHK-Cu, 250-500 mcg/day for BPC-157, and 750 mcg twice weekly for TB-500
Needle Gauge (Thickness) Gauge numbers range from 28G to 31G: Higher gauge = thinner needle